Literature DB >> 6526093

Patient noncompliance in dermatomycosis. Results of a survey among dermatologists and general practitioners and patients.

W Meinhof, R M Girardi, A Stracke.   

Abstract

Noncompliance among dermatomycosis patients exists in many forms and is widespread. Patients are noncompliant in two major areas: they reduce the number of necessary daily applications of the antifungal drug and they prematurely stop the therapy. A survey among 35 dermatologists and general practitioners as well as 230 dermatomycosis patients in Germany in 1982 showed that noncompliance is widespread: a total of 48% of patients neglected the proper daily dosage schedule, 44% reduced the number of daily applications, whereas 4% increased them. 25% of patients stopped treatment after the symptoms had disappeared. However, there is no such thing like the noncompliant patients personality. Depending on the kind of noncompliance, different personality structures appear. And based on the patient's overall attitude towards noncompliance - one third confesses to be noncompliant - the psychological picture becomes even more complex and multifaceted. Improving patient compliance seems to be most promising by better, i.e. more thorough, doctor-patient communication and antifungal drugs that minimize the risks of noncompliant behavior by requiring less daily applications and a shorter time of treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6526093

Source DB:  PubMed          Journal:  Dermatologica        ISSN: 0011-9075


  9 in total

Review 1.  An overview of topical antifungal therapy in dermatomycoses. A North American perspective.

Authors:  A K Gupta; T R Einarson; R C Summerbell; N H Shear
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

Review 2.  Clinical and economic factors in the treatment of onychomycosis.

Authors:  T R Einarson; A K Gupta; N H Shear; S Arikian
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

Review 3.  Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections.

Authors:  R Davis; J A Balfour
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

Review 4.  Bifonazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses.

Authors:  T E Lackner; S P Clissold
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

5.  Increasing patient adherence in antifungal infection treatment: once-daily dosing of sertaconazole.

Authors:  Jeffrey M Weinberg
Journal:  J Clin Aesthet Dermatol       Date:  2009-02

6.  Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task Force against Recalcitrant Tinea (ITART) Consensus on the Management of Glabrous Tinea (INTACT).

Authors:  Madhu Rengasamy; Manjunath M Shenoy; Sunil Dogra; Neelakandhan Asokan; Ananta Khurana; Shital Poojary; Jyothi Jayaraman; Ameet R Valia; Kabir Sardana; Seetharam Kolalapudi; Yogesh Marfatia; P Narasimha Rao; Ramesh M Bhat; Mahendra Kura; Deepika Pandhi; Shyamanta Barua; Vibhor Kaushal
Journal:  Indian Dermatol Online J       Date:  2020-07-13

7.  Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole.

Authors:  H C Korting; M Schäfer-Korting; H Zienicke; A Georgii; M W Ollert
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

8.  Dermatomycoses of the glabrous skin : a double-blind, randomised, comparative trial of sertaconazole 2% cream once daily versus vehicle.

Authors:  Rudy Susilo; Hans C Korting; Uwe Phillip Strauss
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

9.  Efficacy and safety of 1 % terbinafine film-forming solution in Chinese patients with tinea pedis: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study.

Authors:  Ruo Yu Li; A P Wang; J H Xu; L Y Xi; M H Fu; M Zhu; M L Xu; X Q Li; W Lai; W D Liu; X Y Lu; Z Q Gong
Journal:  Clin Drug Investig       Date:  2014-03       Impact factor: 2.859

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.